Dr. Vicky LEE, MD, PhD is Director of Jiahui International Cancer Center (JICC) and Chief of Medical Oncology at JICC, and she has over 30 years of experience in the cancer research and clinical care field. She is an internationally well-known expert in medical oncology, hematology and cancer risk assessment. Dr. LEE has worked 3 years for Peking University First Hospital, and then went to Kyoto University School of Medicine (Japan) and New York University School of Medicine (United States) for further study in breast cancer research and cancer immunology research. Before joining Jiahui Health, Dr. LEE worked in medical oncology for over 20 years in the United States. Since 1995 in US, she has been board certified in American Board of Internal Medicine (ABIM), American Board of Hematology and American Board of Medical Oncology. She received Certificate of Intensive Course in Cancer Genetic Risk Assessment at City of Hope in 2018. She also has Oregon State Medical License and Washington State Medical License.

Dr. LEE is currently a board member of the Washington State Society of Medical Oncology (WSMOS), and is a member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the Oregon Society of Medical Oncology (OSMO).

With solid knowledge and professional training in USA, clinical experience in treating cancer patients, Dr. LEE is familiar with advanced international techniques in cancer prevention, diagnosis and treatment. She is skilled in the treatment of rare and complex cancers, and is adept at communicating with patients and their families. Dr. Vicky LEE always encourages patients to participate in decision making of cancer treatment plan with doctors, as this will enhance patients’ understanding of the disease. Hence, they will corporate well with the treatment plan and achieve better outcome. Dr. LEE cares about patients’ quality of life and good at manage patients’ cancer pain through standardized and individualized treatment plans.

Dr. LEE specializes in hematology and oncology treatment including but not limited to:

· Treatment of solid tumor, special interest in breast cancer, melanoma, colon cancer, and lung cancer.
· Management of blood tumors, especially in myeloma and lymphoma.
· Diagnosis and treatment of benign hematological diseases involving antithrombotic therapy and management of myeloproliferative disorders, MDS.
· Cancer Genetics consultation and cancer risk assessment.
· Palliative Care and Management of cancer pain.

Dr. Andrew X. ZHU, MD, PhD serves as a multi-site practice physician at Jiahui International Cancer Center. Dr. Andrew X. Zhu is an internationally recognized leader in hepatocellular carcinoma(HCC) and cholangiocarcinoma, Dr. Zhu has served as a principle investigator in many pivotal clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers.

Dr. Andrew X. Zhu is a founding board member of the International Liver Cancer Association(ILCA), Fellow of American College of Physicians (ACP), and a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR) and former Professor of Medicine at Harvard Medical School.

Dr. Andrew X. Zhu established the multidisciplinary liver cancer clinic and conference at Massachusetts General Hospital in 2009. The hepatobiliary cancer MDT included experts from Surgical Oncology, Transplant Surgery, Interventional Radiology, Radiation Oncology, Hepatology and Pathology. In addition, Dr. Andrew X. Zhu led a series of pivotal clinical studies in advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma(BTC) during his tenure as director of Liver Cancer Research at the Mass General Cancer Center. As the lead global principal investigator, he led the pivotal studies which led to the regulatory approval of pembrolizumab and ramucirumab in advanced HCC. As a co-principal investigator, he is lead the phase III trial of first IDH-1 inhibitor Ivosidenib in cholangiocarcinoma with IDH-1 mutations, which has met the primary endpoint. Under the leadership of Dr. Andrew X. Zhu, he and his team established the hepatocellular cancer treatment center in New England, USA, which has become one of the most active clinical research centers for liver cancer in the United States.

Dr. Lily ZHOU serves as Section Head of Hematology at Jiahui International Cancer Center. Dr. Zhou graduated from the Second Military Medical University in 2004 with Master of Medicine, and earned her PhD in the affiliated Shanghai Changzheng Hospital in 2007. During 2012 and 2014, she completed her post-doctoral work in the Hematology/Oncology Department of University of California, San Francisco (UCSF), US. Prior to joining Jiahui, Dr. Zhou served as an associate professor oncologist with an expertise in hematology at Shanghai Changzheng Hospital. Being a hematologist for more than ten years, and served a chief physician in hematology, she specializes in the diagnosis and treatment of myeloma, lymphoma and leukemia, as well as benign hematological disorders such as anemia, thrombocytopenia, coagulation dysfunction, etc.

Dr. Zhou has successively presided over the projects funded by the Translational Medicine of Myeloma at UCSF, National Natural Science Foundation, Shanghai Thousand Talents program and the Myeloma Program of Chinese Medical Doctor Association. She has participated in several international multi-site clinical trials, as well as some national and civic trials. As a first author, she has published more than ten SCI papers.

Dr. Zhou is a committee member of Hematology Society of shanghai medical association, translational hematology committee of the Shanghai medical association, and youth committee member of the hematology rehabilitation committee of the Chinese medical association, also a member of the American cancer association (ASCO), and a committee member of the experimental diagnostics and transplantation immunology group of the hematology branch of the Chinese medical association.

Dr. LI Ping serves as a Multi-site oncologist at Jiahui International Cancer Center and a chief physician in hematology in Shanghai Tongji Hospital, as well as a Professor and Doctoral Supervisor in Tongji University School of Medicine.

Graduated from Soochow University Medical School in 1999, Dr. Li studied in Japan in 2003 and received her MD degree from Nagoya University in 2009. After graduating, she studied at the Aichi Oncology Hospital in Japan for more than three years and returned to China in 2012 to work at Shanghai Tongji Hospital.

Dr. Li specializes in diagnosis and treatment of hematological malignancies such as leukemia, myeloma, and lymphoma, especially in study and clinic application of CAR-T cell therapy (with over 500 CAR-T treated patients) .

Dr. Li is recently a youth committee member of the hematology branch of the Chinese medical association, a member of the lymphoma committee of the Chinese Anti-Cancer Association, a member of the committee of the blood immunity branch of the Chinese Society for Immunology, a member of the committee for biological therapy of the Chinese Research Hospital Association, a deputy director of youth committee member of the lymphoma committee of the Shanghai Anticancer association, a standing committee member of the hematology branch of the Shanghai Association of Chinese Integrative Medicine, and a member of the committee of the blood immunity branch of the Shanghai Society for Immunology.. She has presided over 2 projects funded by the National Natural Science Foundation of China (NSFC), and participated in many key R&D projects of the Ministry of Science and Technology, national projects and Shanghai Science and Technology Commission projects. She has published more than 30 papers, including more than 10 SCI papers as first author or corresponding author.

Dr. Li Junmin, MD, PhD, currently serves as the Director of the Hematology Department at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. He holds the positions of vice president of the Hematology Branch of the Chinese Medical Doctor Association (CMDA), president of the Hematology Branch of the Chinese Geriatrics Society, chairman of the Shanghai Hematology Branch of the Chinese Medical Association (CMA), chairman of the Shanghai Hematology-Oncology Committee of the China Anti-Cancer Association, vice president of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care, and chief scientist of the tumor mRNA vaccine key project supported by the Ministry of Science and Technology.

Pr. Li has been engaged in clinical and scientific research in the field of hematology in internal medicine for a long time. He has extensive experience in the pathogenesis and treatment of hematological malignancies and immune-related blood disorders. He has been the principal investigator for four projects funded by the National Natural Science Foundation and one key project of the Ministry of Science and Technology of the PRC. He has also successfully led an 863-Initiative research project and one special project sponsored by the Ministry of Health of the PRC. At the provincial and ministerial levels, he has undertaken five research projects, including those supported by the Ministry of Education of the PRC and the Shanghai municipality.

Pr. Li has an impressive publication record, with nearly a hundred papers published in domestic and international academic journals. Among his accolades are the prestigious National Science and Technology Award, the Ministry of Education Scientific and Technological Achievement Award, the Shanghai Science and Technology Progress Award, and the Shanghai Medical Science and Technology Award. His expertise lies in the field of hematological malignancies, focusing on diseases affecting the blood system such as leukemia, lymphoma, multiple myeloma, and immune-related blood disorders like idiopathic thrombocytopenic purpura. 

Dr. Hu Jiong currently holds the positions of Deputy Director of the Hematology Department and Director of the Bone Marrow Transplantation (BMT) Unit at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Dr. Hu is a full member of the American Society of Hematology, serving on the Academic Committee of Myeloid Neoplasm. He is also a distinguished member of the Global Committee of the European Society for Blood and Marrow Transplantation (EBMT). In addition to his impressive affiliations, Dr. Hu serves as the vice president of the Shanghai Hematology Physicians Branch of the Chinese Medical Association, and the deputy director of the Shanghai Society for Transplant Immunology.

Pr. Hu has contributed his expertise to the Hematology Department for adults at Saint-Louis Hospital in Paris, France, as well as the prestigious Bone Marrow Transplantation Center at Queen Mary Hospital, Hong Kong, China. In 2023, he successfully completed his postdoctoral research at the esteemed National Heart, Lung, and Blood Institute (NIH-NHLBI) in the United States.

Pr. Hu has dedicated his career to advancing both basic and clinical research in the field of hematopoietic stem cell transplantation. His primary focus has been on optimizing clinical treatment systems and exploring drug resistance mechanisms and targeted reversal therapies in leukemia. His remarkable contributions include leading four projects funded by the prestigious National Natural Science Foundation, receiving a research grant from the Shanghai Outstanding Young Physician Program, and having published over 100 SCI papers.

In recognition of his outstanding achievements, He has been awarded the second prize of the National Natural Science Award in 2016 (as the fourth contributor), the grand prize of the Shanghai Natural Science Award in 2015 (as the fourth contributor), and the 2022 EBMT Young Leader Award.

Dr. Qi is an oncologist at Jiahui International Cancer Center. Dr. Qi graduated from Shanghai Jiaotong University School of Medicine in 2012 with master’s degree in Respiratory Medicine, and earned her Ph.D. in Oncology in 2017 from Tongji University School of Medicine. During 2015 and 2016, she worked at M.D. Anderson Cancer Center as a visiting scientist. Before joining Jiahui Health, Dr. Qi served as a vice-chief physician in the Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University. Dr. Qi specializes in diagnosis and treatment of solid tumor, especially lung cancer. She also performed the operation of bronchoscopy and CT-guided transthoracic percutaneous fine needle aspiration and core biopsy. 

As for scientific research, Dr. Qi has participated in several international and domestic multi-center clinical trials for anti-cancer drugs. She has presided over youth fund of national natural science foundation of China (NSFC) and has been involved in the research of drug resistance in lung cancer. As the first author, she has published more than 10 peer-reviewed papers in SCI Journals. 

Dr. WANG Hongzhe is currently an oncologist at Jiahui International Cancer Center. Dr. Wang graduated from Guangxi Medical University in 2008 with a Master's degree in Internal Medicine. After graduation, Dr. Wang has long been engaged in front-line clinical work and has participated in many clinical teaching and research exchanges with the Dana-Farber Cancer Institute (DFCI) in China. Dr. Wang insists on the principle of individualized treatment in the diagnosis and comprehensive medical treatment of common malignant tumors in medical oncology. He specializes in diagnosis and comprehensive treatment of malignant lymphoma, lung cancer, breast cancer and other malignant tumors.

Dr. MAO Aiqin is currently a medical oncologist at Jiahui International Cancer Center. She graduated from Xin Xiang Medical College with a bachelor's degree in 1997 and was engaged in teaching and clinical research of internal medicine at the affiliated Hospital of Henan Polytechnic University. In 2010, she received her master's degree in Clinical Oncology from Guang Xi Medical University. After graduation, she has been working in clinical practice and has rich knowledge in internal medicine and oncology.

Before joining Jiahui, Dr. Mao served as the associate chief physician at the Third Ring Hospital of Cancer Hospital of Chinese Academy of Medical Sciences and the Department of Oncology of Boao Evergrande International Hospital. She has long been engaged in front-line clinical work in the department of oncology and has accumulated rich clinical experience. Dr. Mao specializes in standardized chemotherapy and palliative treatment of many cancer types, especially for precision personalized treatment for lung and breast cancer. She is also a highly responsible individual who is patient-centered.

In terms of clinical research, Dr. Mao has participated in many clinical trials/projects and has published many clinical oncology-related papers.

Dr. Dong Yan is currently serving as a medical oncologist at Jiahui International Cancer Center. She graduated with a bachelor’s degree in Clinical Medicine from Peking University Health Science Center in 2002 and received her Ph.D. from the Graduate School of Medicine at the University of Tokyo in 2008. Before joining Jiahui Health, Dr. Dong worked at Tongji Hospital in Shanghai.

Dr. Dong has dedicated her career to clinical and research work in hematology. She is highly proficient in diagnosing and treating a wide range of common blood disorders, including various types of anemia, leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes (MDS), and thrombocytopenia. She has also accumulated clinical experience in advanced blood cancer therapies such as autologous stem cell transplantation, allogeneic hematopoietic stem cell transplantation, and CAR-T.

Dr. Dong has published several papers in both domestic and international core journals and is currently a committee member of the Hematology Branch of Shanghai Medical Association（SMA）.

Dr. Lisa FENG is currently a medical oncologist of Jiahui International Cancer Center, graduated from the First Affiliated Hospital of Zhengzhou University with a Master of Medicine degree (hematology) in 2013. Before joining Jiahui Health, she has worked in two hematonosis hospitals. During 6 years of clinical practice, she has accumulated experience in advanced hematology oncology treatments such as allogeneic hematopoietic stem cell transplantation and CAR-T. Dr. Feng specializes in the treatment of common benign and malignant hematological diseases such as leukemia, lymphoma, myelodysplastic syndrome and aplastic anemia, including allogeneic hematopoietic stem cell transplantation techniques and CAR-T techniques.

Dr. SHAO Yilin is currently an oncologist at Jiahui International Cancer Center. Dr. Shao graduated from Shanghai Medical College Fudan University (8-year program in clinical medicine) with a Ph.D. in oncology. She was granted the outstanding graduate of Fudan University. Before joining Jiahui Health, Dr. Shao completed her standardized training of residents at Fudan University Shanghai Cancer Center and then worked at the Cancer Centre of Shanghai Tenth People’s Hospital. Dr. Shao has several years of clinical experience in medical oncology, especially in diagnosis and treatment of breast cancer and other common cancer. She has been involved in various clinical research projects and has published several SCI papers.

Dr. Volker RUDAT is the Consultant of the Department of Radiation Oncology at Jiahui International Cancer Center, and Professor of Radiation Oncology at the University Hospital Hamburg (UKE), Germany. 

He received his scientific and clinical education at the German Cancer Research Center (dkfz) and University of Heidelberg, Germany. In 2001, he was appointed Professor and Vice Director of the Department of Radiation Oncology of the University Hospital Hamburg (UKE) and in 2006, Director of the Department of Radiation Oncology of the St. Josef University Hospital, Bochum, Germany. Dr. Rudat followed an invitation to Al Khobar, Saudi Arabia, where he and his team established a large Oncology Center. 

Dr. Rudat has performed many clinical and radiobiological studies which are reflected in more than 100 international scientific publications. He contributed scientifically to the development of concomitant radiochemotherapy, intensity-modulated radiotherapy (IMRT), and image-guided radiotherapy (IGRT). Dr. Rudat served as a principal investigator of a German prospective multicenter study establishing larynx function preserving therapy in Germany. Apart from the radiotherapy and radiochemotherapy of head and neck cancer, his clinical and scientific interest focuses on the radiotherapy of breast cancer, prostate cancer, lung cancer, rectal cancer, and other malignant tumors and benign conditions.

*Scientific publications Dr. Volker RUDAT

Dr. WANG Bin serves as a radiation oncologist of Jiahui International Cancer Center. Dr. Wang obtained the bachelor degree of Clinical Medicine from Zhengzhou University School of Medicine in 1999, and then he received the master degree in medical oncology and Ph.D. in pathology at Shanghai Secondary Millitary University. Before joining Jiahui Health, he served as attending physician in the Center of Clinical Oncology, Shenzhen Hospital, Hong Kong University and Department of Radiation at a private cancer center in Shanghai. In 2018, he visited the Cancer Center of Queen Mary Hospital, Hong Kong University and Pamela Youde Nethersole Eastern Hospital. Being a radiation oncologist for more than ten years, he specializes in conventional radiation therapy and stereotactic radiotherapy of various tumors, especially the treatment of gastrointestinal, breast, and head & neck cancers. In addition, he also pays close attention to the cardiac toxicity during breast cancer radiotherapy.

Dr. Wang joined as sub-investigators in a global multi-center clinical trials for liver cancer radiotherapy and a HCC basic research supported by National Natural Science Foundation of China.

He had several academic publications. He had participated in the translation of the English version of Proton Therapy by MDACC and Target Volume Delineation for Conformal and Intensity-Modulated Radiation Therapy by Nancy Y. Lee.
Dr. Wang is a current member of Chinese Society of Clinical Oncology (CSCO).

Dr. YANG Fang is currently serving as a medical oncologist at Jiahui International Cancer Center. She graduated with a Bachelor's degree in Clinical Medicine from Harbin Medical University in 2004 and obtained a Master's degree in Oncology from Harbin Medical University in 2007. From 2012 to 2013, she has studied at the Cancer Hospital Affiliated to Fudan University and the Cancer Center of West China Hospital. In 2018, she received training in breast cancer diagnosis and treatment at Dana-Farber Cancer Center in the United States. Dr. Yang has been practiced oncology for more than fifteen years. She is very knowledgeable in diagnosing and treating a wide variety of solid tumors, including breast cancer, GYN malignancies, lung cancer, GI malignancies, etc. She is also good at palliative care for terminal cancer patients. Dr. Yang has experience working in general tier 1 hospital, tertiary cancer hospital, and international hospital. She was in charge of international consultation for complicated cancer patients. She is also licensed as a psychologist and health management. 

Dr. ZHANG Lihua serves as an attending physician in radiation oncology department of Jiahui International Cancer Center. Dr. Zhang completed her six-year clinical medical program in Japanese at Norman Bethune Health Science Center of Jilin University in 2003. She obtained her clinical master degree from Obstetrics & Gynecology Hospital of Fudan University and PhD degree of Oncology from Fudan University Shanghai Cancer Center. Since 2012, Dr. Zhang has received extensive training in Internal Medicine and undergone resident standardization training and specialist training in Radiotherapy at Shanghai Sixth People's Hospital. In October 2014, she visited Heidelberg University Medical School in Germany, focusing on intraoperative radiotherapy techniques for breast cancer, pancreatic cancer, and gynecological tumors. With over ten years of experience in radiation oncology department, Dr. Zhang also serves as a national instructor for resident standardization training and specialist training in radiation oncology.

Dr. Zhang specializes in the comprehensive treatment of a wide range of cancers through radiotherapy and chemotherapy. Her expertise extends to gynecological tumors, including cervical, vaginal, and endometrial cancers; gastrointestinal tumors such as esophageal, pancreatic, stomach, intestinal, and liver cancers; head and neck tumors like nasopharyngeal, nasal sinus, ear canal, parotid gland, and gliomas; thoracic tumors including lung and thymus cancers; and urological tumors encompassing bladder, kidney, ureteral, and prostate cancers. Furthermore, Dr. Zhang is adept in treating soft tissue tumors, bone tumors, lymphomas, myelomas, breast cancer, and benign conditions such as synovitis, heterotopic ossification, and keloids with advanced radiotherapy techniques. These techniques include adaptive radiotherapy, intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), intraoperative radiation therapy (IORT), stereotactic body radiotherapy (SBRT), and brachytherapy. She is particularly experienced in using AI-assisted radiotherapy for the treatment of complex, recurrent, and metastatic tumors, and re-irradiation, especially in brachytherapy for gynecological tumors.

Dr. Zhang has published dozens of articles in Chinese and English, primarily involved in three projects at the directorate and municipal science committee level related to cervical cancer and esophageal cancer. Currently, she is a member of the youth committee of radiotherapy branch of the Shanghai Medical Association, and a member of the youth radiotherapy committee of the Shanghai Anti-Cancer Association.

Dr. XU Rong serves as an attending physician in medical oncology department of Jiahui International Cancer Center. Dr. Xu got her Bachelor’s Degree in Clinical Medicine in 2003 and Medical Master’s Degree in Hematology in 2007 from Shanghai Jiaotong University School of Medicine. From 2007 to 2017, Dr. Xu worked in the First People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine. Before joining Jiahui, Dr. Xu was in charge of the HSCT unit in a hematology hospital, specializing in autologous and allogeneic hematopoietic stem cell transplantation and CAR-T cell therapy for relapsed and refractory hematologic tumors. She is adept at managing complications in allogeneic hematopoietic stem cell transplantation, treating post allogeneic HSCT problems such as GVHD, infections, primary and secondary graft failure, thrombotic complications, tumor relapse, etc. Dr. Xu also has extensive experience in autologous hematopoietic stem cell transplantation for multiple myeloma and lymphoma, and CAR-T cell therapy including auto-HSCT bridging CAR-T, tandem CAR-T, double-target CAR-T. Dr. Xu has mastered the technology of invasive and non-invasive mechanical ventilation, continuous renal replacement therapy, hemodynamic monitoring, and intensive rehabilitation techniques. Dr. Xu is qualified in internal medicine, critical care medicine and rehabilitation medicine. As for academic field, she has published more than ten Chinese core journal articles and two SCI papers.

Dr. XUE Peng is an oncologist at Jiahui international cancer center major in solid tumor. He graduated from Shanghai Second Medical University with Bachelor degree in 2000. And he had three years of research experience in state key laboratory of oncogenes ＆ related genes at Shanghai Cancer Institute from 2000 to 2003. Then he achieved Master degree in clinical oncology at Shanghai Jiaotong University School of medicine in 2006. Before joining Jiahui Health, he has served as an attending physician in the oncology department of Shanghai General Hospital since 2006. And he obtained the Ph.D. in clinical oncology during the work. He received academic funding of Sasagawa fellowship to participate medical research in Kyoto University Hospital in Japan from 2012 to 2013.

Dr. Xue specializes in diagnosis and treatment of solid tumor, especially gastrointestinal cancer, pancreatic cancer, breast cancer, lung cancer etc. He had published several peer-reviewed paper in the field of chemotherapy for pancreatic cancer patients.

Now Dr. Xue is a member of Chinese Society of Clinical Oncology and Japan-china Medical Association.